ASLAN003 is an investigational small molecule drug primarily studied for its potential in treating autoimmune and inflammatory diseases. It functions by selectively targeting key signaling pathways involved in immune cell activation, thereby modulating abnormal immune responses. Its application is being explored in conditions such as lupus and other chronic inflammatory disorders where conventional therapies have limited efficacy or significant side effects. Due to its targeted mechanism, ASLAN003 offers the possibility of improved safety and reduced immunosuppression compared to broad-acting drugs. It is currently in clinical development, with ongoing trials assessing its effectiveness, optimal dosing, and long-term tolerability in patient populations.